Trial Profile
A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline or Somatic BRCA1/2 Mutations
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms LUCY
- Sponsors AstraZeneca; AstraZeneca AB
- 08 Mar 2024 This trial has been completed in Italy according to European Clinical Trials Database record.
- 02 Nov 2021 Status changed from active, no longer recruiting to completed.
- 28 Oct 2021 This trial has been completed in Germany and Hungary, according to European Clinical Trials Database record.